Moonwalk Biosciences raises $70M to advance siRNA obesity therapy
read at Endpoints ↗DealPositive
Moonwalk Biosciences announced it has secured $70 million in financing to move its obesity program into clinical testing.
The funding will support development of a small interfering RNA (siRNA) therapeutic aimed at reducing body weight, marking a shift toward genetic-medicine approaches for obesity.
The capital raise positions the company to begin first-in-human trials, highlighting investor confidence in the potential of RNA-based treatments for metabolic disease.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Moonwalk raises $70M to test siRNA treatment for obesity”
read at Endpoints ↗81 words · retrieved Sep 8
comments(0)
5-min edit window · permanent after that